The European Medicines Agency (EMA) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) recently released new draft guidance for pharmaceutical companies on how they can maintain data integrity in the process of testing, manufacturing, packaging, distributing, and monitoring medicines.
Regulators rely on such data to evaluate the quality, safety, and efficacy of medicines and to monitor their benefit-risk profile throughout the lifecycle of the product.
